Announcement 28.02.2012 List of NeuroSearch announcements from January 2011 to February 2012 In accordance with section 27b of Consolidated Act about Securities Trading etc., we hereby issue a complete list of NeuroSearch announcements from January 2011 to February 2012. All announcements are available under the IR section of the company's website: www.neurosearch.com. Date No. Title -------------------------------------------------------------------------------- 10.01.2011 01-11 ATP, AES and SUPP’s ownership in NeuroSearch has been reduced to less than 10% -------------------------------------------------------------------------------- 11.01.2011 02-11 NeuroSearch announces a restructuring of the company to support and strengthen strategic focus -------------------------------------------------------------------------------- 23.02.2011 03-11 NeuroSearch A/S – Annual General Meeting -------------------------------------------------------------------------------- 10.03.2011 04-11 NeuroSearch A/S – Financial statements and release of Annual Report 2010 -------------------------------------------------------------------------------- 10.03.2011 05-11 List of NeuroSearch announcements in 2010 and in January - March 2011 -------------------------------------------------------------------------------- 22.03.2011 06-11 Luxor Capital Group’s ownership in NeuroSearch has been increased to more than 5% -------------------------------------------------------------------------------- 23.03.2011 07-11 NeuroSearch provides an update on the development plan for Huntexil® in the treatment of Huntington's disease following the End of Phase II meeting with the FDA -------------------------------------------------------------------------------- 28.03.2011 08-11 Notice convening Annual General Meeting of NeuroSearch A/S -------------------------------------------------------------------------------- 04.04.2011 09-11 NeuroSearch announces that the first patient has enrolled in the Open HART safety extension study with Huntexil® -------------------------------------------------------------------------------- 27.04.2011 10-11 NeuroSearch A/S – Interim report for Q1 2011 -------------------------------------------------------------------------------- 27.04.2011 11-11 Report on Annual General Meeting held in NeuroSearch A/S -------------------------------------------------------------------------------- 03.05.2011 12-11 NeuroSearch announces that Beckman Coulter becomes co-owner of Atonomics to support the development of products for local diagnostics based on the company's unique Atolyzer®-platform -------------------------------------------------------------------------------- 16.05.2011 13-11 NeuroSearch extends the R&D alliance with Janssen -------------------------------------------------------------------------------- 17.05.2011 14-11 Luxor Capital Group’s ownership in NeuroSearch has been increased to more than 10% -------------------------------------------------------------------------------- 24.05.2011 15-11 NeuroSearch reports on scientific advice from the EMA on the clinical development programme for Huntexil® -------------------------------------------------------------------------------- 26.05.2011 16-11 NeuroSearch reports on scientific advice received from the FDA and EMA concerning the clinical development programme for tesofensine -------------------------------------------------------------------------------- 30.06.2011 17-11 NeuroSearch updates on the clinical development programme for Huntexil® -------------------------------------------------------------------------------- 06.07.2011 18-11 NeuroSearch concludes agreement with Biolin Scientific regarding the sale of Sophion Bioscience -------------------------------------------------------------------------------- 19.08.2011 19-11 Release date for the NeuroSearch H1 interim report -------------------------------------------------------------------------------- 25.08.2011 20-11 NeuroSearch A/S – H1 Report 2011 -------------------------------------------------------------------------------- 15.09.2011 21-11 NeuroSearch attended the World Congress on Huntington's Disease -------------------------------------------------------------------------------- 27.09.2011 22-11 NeuroSearch provides update on the Huntexil® development programme and plans a comprehensive restructuring of the company’s operations -------------------------------------------------------------------------------- 06.10.2011 23-11 Major shareholder announcement / Porter Orlin LLC -------------------------------------------------------------------------------- 25.10.2011 24-11 NeuroSearch announces changes in management -------------------------------------------------------------------------------- 08.11.2011 25-11 NeuroSearch publishes the MermaiHD study in The Lancet Neurology -------------------------------------------------------------------------------- 10.11.2011 26-11 NeuroSearch – Release date for Q3 report 2011 -------------------------------------------------------------------------------- 17.11.2011 27-11 NeuroSearch A/S – Q3 report 2011 -------------------------------------------------------------------------------- 09.12.2011 28-11 NeuroSearch – Financial calendar for 2012 -------------------------------------------------------------------------------- 15.12.2011 29-11 NeuroSearch research creates a basis for the establishment of new biotech company named Acesion Pharma -------------------------------------------------------------------------------- 16.12.2011 30-11 Leading NeuroSearch employees establish new research and development company named Aniona -------------------------------------------------------------------------------- 16.12.2011 31-11 Major shareholder announcement / Porter Orlin LLC -------------------------------------------------------------------------------- 23.12.2011 32-11 NeuroSearch announces changes to the A. Carlsson Research AB share purchase agreement -------------------------------------------------------------------------------- 26.01.2012 01-12 Notice convening Extraordinary General Meeting in NeuroSearch A/S -------------------------------------------------------------------------------- 10.02.2012 02-12 NeuroSearch announces a change to the date of the Annual General Meeting 2012 -------------------------------------------------------------------------------- 10.02.2012 03-12 NeuroSearch – Financial calendar for 2012 -------------------------------------------------------------------------------- 20.02.2012 04-12 Report on Extraordinary General Meeting in NeuroSearch A/S -------------------------------------------------------------------------------- 22.02.2012 05-12 Release date for the financial statements 2011 for NeuroSearch A/S and subsequent telephone conference -------------------------------------------------------------------------------- 28.02.2012 06-12 NeuroSearch announces the company's Annual Report 2011 -------------------------------------------------------------------------------- Patrik Dahlen CEO Contact person: René Schneider, EVP & CFO, telephone: +45 4460 8700 or +45 2911 2097 About NeuroSearch NeuroSearch A/S (NEUR) is a European-based biopharmaceutical company listed on NASDAQ OMX Copenhagen A/S and specialising in central nervous system (CNS) disorders. The vision is to develop NeuroSearch into a profitable specialty pharmaceutical company. The strategy is to complete the development and subsequently to market Huntexil®, a unique drug in clinical Phase III for the treatment of the motor symptoms of Huntington’s disease. As a consequence of the restructuring of NeuroSearch that was announced 27 September 2011, the company also has a portfolio of assets for outlicensing or divestment.